Current TCR Studies
What type of study are you interested in?
Acne
Therapeutics Clinical Research has a research study to evaluate the efficacy and safety of a novel investigational medication for patients with moderate to severe acne.
Inclusion Criteria
- Males and females age 18 years and older
- Clinical diagnosis of moderate to severe acne
- Acne which has been unresponsive to oral antibiotics
Exclusion Criteria
- Use of certain medications or treatments (to be discussed)
- Recent history of drug or alcohol abuse
- Skin diseases that may interfere with evaluation
- Pregnant, planning a pregnancy or nursing
New Topical Medication for Rosacea
Therapeutics Clinical Research is doing research to evaluate the effectiveness and safety of a new investigational topical medication for patients with moderate to severe rosacea.
Inclusion Criteria:
- Males and females age 18 years and older
- Moderate to severe papulopustular rosacea
Exclusion Criteria:
- Other forms of rosacea or facial dermatoses that may be confounded with papulopustular rosacea
- Underlying known disease or surgical/medical condition
- Clinically significant abnormal lab values
- A beard that would interfere with study treatment and assessment
- Female who is breast feeding, pregnant, or planning to become pregnant
Thinning Hair
Therapeutics Clinical Research is conducting a medical research study of an investigational product for thinning hair.
Inclusion Criteria
- Adult women, age 18 to 59
- Adult men, age 18 to 49
- General good health
- Have hair loss
- Willing to maintain the same hairstyle, color and hair regimen throughout the study
Exclusion Criteria
- Pregnant, planning a pregnancy or breastfeeding women
- Abnormalities of the scalp
- Underlying medical problems such as HIV, uncontrolled systemic disease, uncontrolled hyper- or hypothyroidism
- Hair transplants or scalp reductions
- Use of hair weaves, extensions or wigs within 3 months prior to study entry
Onychomycosis (Toenail Fungus) Study
Do you have thick, discolored toenails? If so, you may have a fungal infection called onychomycosis - and you are not alone. Millions of adults like you struggle with the constant embarrassment of yellow, brittle toenails. This condition can easily spread to your other nails (even from foot to hand) or to your family members. If you are frustrated by this condition, you may qualify for a medical research study. The study is for an investigational, clear medication for nail fungus (applied directly to the nail) that may help.
To see if you might qualify, please call (619) 512-DERM (3376) or e-mail us at info@therapeuticsresearch.com
Rosacea Study
Therapeutics Clinical Research is conducting a medical research study of an investigational drug for adults with facial bumps caused by rosacea.
Inclusion Criteria:
- Adults 18 and older
- General good health
- 5-40 papules on the face caused by papulopustular rosacea
Exclusion Criteria:
- Pregnant, planning a pregnancy or breastfeeding women
- Topical or oral use of dapsone
- Current use of niacin > 500mg/day
- Use of light of laser therapy within 3 months
- Ocular rosacea
- Use of tanning beds or other intense UV exposure during the study (mountain sports, sunbathing, etc.)
- Participation in another investigational drug trial within 30 days
Atopic Dermatitis Studies
Study 1
Therapeutics Clinical Research will be conducting a clinical research study on a naturally derived investigational product for control of Atopic Dermatitis
If you:
- Have atopic dermatitis (a type of eczema)
- Are 18 years of age or older
Qualified participants will receive at no cost:
- Study related medical examinations and testing
- Investigational study product (no placebo)
Compensation up to $400 for completing all visits of the study. If you're interested in finding out more about this clinical study, please contact Therapeutics Clinical Research at (619) 512-DERM (3376) or e-mail us at info@therapeuticsresearch.com
Study 2
Therapeutics Clinical Research is now enrolling a study to evaluate a topical investigational medication for pediatric patients with moderate to severe atopic dermatitis.
Key Inclusion Criteria:
- Children age 3 months to under 18 years of age
- Minimum weight of 8 pounds
- Clinical diagnosis of moderate to severe Atopic Dermatitis or Eczema (25% BSA)
- In general good health
- Willing to avoid constant sun exposure, tanning beds or other UV light sources
- If female is of child-bearing potential, she must have a negative urine pregnancy test and use an acceptable form of birth control (including abstinence0
Key Exclusion Criteria:
- Participation in another clinical research study
- Pregnant or lactating females
- Clinically infected Atopic Dermatitis
- Known history of Atopic Dermatitis that is unresponsive to topical steroids
- Any significant medical condition likely to interfere with evaluations, such as:
- Skin disorders (i.e. Netherton's Syndrome, psoriasis, dermatologic fungal infections)
- Pigmentation or extensive scarring in treatment areas
- Significant Systemic Disease such as immunological deficiencies or HIV
- Unstable medical disorders such as diabetes or hypertension
- Life-threatening disease or current malignancies
If you're interested in finding out more about this clinical study, please contact Therapeutics Clinical Research at (619) 512-DERM (3376) or e-mail us at info@therapeuticsresearch.com
Study 3
Therapeutics Clinical Research is conducting a medical research study of an investigational topical product for volunteers with moderate to severe eczema or atopic dermatitis.
Key Inclusion Criteria:
- Adults, age 18 to 65
- General good health
- Moderate to severe atopic dermatitis for at least 12 months
Key Exclusion Criteria:
- Pregnant, planning a pregnancy or breastfeeding women
- Underlying medical problems such as liver disease, impaired kidney function or uncontrolled systemic disease
- Inability or unwillingness to undergo multiple venipunctures because of poor tolerability or lack of access to veins
Psoriatic Arthritis Study
This study is designed to evaluate an investigational treatment option for patients who are suffering from active psoriatic arthritis. The purpose of the study is to see if an investigational drug, which is being developed for treating psoriatic arthritis, is safe and effective.
Inclusion Criteria:
- Eighteen years or older
- Diagnosed as having psoriatic arthritis for at least six months
- Have active plaque psoriasis or documented history of plaque psoriasis
- Willing to avoid prolonged sun exposure and avoid use of tanning booths or other ultraviolet light sources during study.
Exclusion Criteria:
- Pregnant, nursing, or planning pregnancy
- Other inflammatory diseases that could interfere with study therapy assessment
- Prior use of any therapeutic agent targeted at reducing IL-12 or IL-23, including but not limited to ustekinumab and ABT-874.
- Have HIV, hepatitis B, or hepatitis C
- Have current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, cerebral, or psychiatric disease
- History of any clinically significant medical illness or disorder that in the physician's opinion would put the patient at risk or interfere with the patient's participation.
- Enrolled in another study of an investigational drug or device
Psoriasis Study Opportunities
Clinical research study to evaluate a new investigational drug in adults with moderate to severe plaque psoriasis.
Study 1
Therapeutics Clinical Research has a research study to evaluate the efficacy and safety of a Vitamin D derivative for patients with moderate to severe plaque psoriasis type.
Inclusion Criteria:
- Adults age 18 and older
- Clinical diagnosis of moderate to severe plaque psoriasis on body
- Up to 20% surface area affected with plaque psoriasis with at least a 10 cm2 affected area
Exclusion Criteria:
- Non-plaque psoriasis
- Pregnant, planning a pregnancy or nursing
- Allergy to Vitamin D3 derivative preparation
- Presence of contact dermatitis
- Underlying disease or a surgical or medical condition such as renal or liver insufficiency, cardiac or hepatic disease
- Patients that are using lithium, beta-blockers or chloroquine must be on a stable dose with a stable psoriatic condition for more than 12 weeks
- Patients that are taking oral vitamin D supplement must be on a stable dose for at least 8 weeks
- Use of medications that affect the immune system (i.e. methotrexate, oral retinoids, oral steroids, cyclosporine, biologics)
- Use of phototherapy during the study
- Use of creams and lotions not approved by study conductors
Study 2
Therapeutics Clinical Research has a research study to evaluate the efficacy and safety of an investigational topical ointment for patients with plaque psoriasis.
Overview of Inclusion Criteria:
- Adults age 18 years of age or older
- Clinical diagnosis of plaque psoriasis on body
- 25% or more body surface area (excluding the scalp) affected with plaque psoriasis
- Ability to attend 10 office visits over 15 days
Overview of Exclusion Criteria:
- Non-plaque psoriasis
- Pregnant, planning a pregnancy or nursing
- Underlying disease or a surgical or medical condition such as cancer, HIV or TB
|
